BCM
VYNE icon

Bridgeway Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Bridgeway Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-76,958
Closed -$25.8K – 1290
2025
Q3 		$25.8K Hold
76,958
– – ﹤0.01% 1186
2025
Q2 		$127K Buy
76,958
+25,000
+48% +$32.5K ﹤0.01% 1035
2025
Q1 		$82.1K Buy
51,958
+15,000
+41% +$36.9K ﹤0.01% 1071
2024
Q4 		$124K Buy
+36,958
New +$96.7K ﹤0.01% 1085
2020
Q2 		– Sell
-1,465
Closed -$283K – 1406
2020
Q1 		$283K Sell
1,465
-417
-22% -$131K 0.01% 948
2019
Q4 		$629K Buy
1,882
+33
+2% +$11K 0.01% 885
2019
Q3 		$596K Buy
1,849
+20
+1% +$6.46K 0.01% 877
2019
Q2 		$789K Hold
1,829
– – 0.01% 815
2019
Q1 		$1.03M Buy
1,829
+94
+5% +$45.1K 0.01% 754
2018
Q4 		$515K Hold
1,735
– – 0.01% 991
2018
Q3 		$1.23M Buy
+1,735
New +$1.07M 0.01% 799

Other funds holding VYNE

SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's VYNE Position: Q4 2025 in Review

Bridgeway Capital Management sold out of VYNE Therapeutics (VYNE) in Q4 2025, closing a stake of 76,958 shares — an estimated $25.8K sold.

Bridgeway Capital Management first reported a position in VYNE in Q3 2018 and held it in 11 quarters. The position peaked at $1.23M in Q3 2018. 44 funds tracked by Wall St. Rank hold VYNE as of Q4 2025.

  • Bridgeway Capital Management reported no remaining VYNE Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 76,958 VYNE Therapeutics shares in Q4 2025, an estimated $25.8K.
  • Bridgeway Capital Management first reported a position in VYNE Therapeutics in Q3 2018 and held it in 11 quarters.
  • Bridgeway Capital Management's VYNE Therapeutics position peaked at $1.23M in Q3 2018.
  • 44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.